Holen Sie sich die Stockscreener-App
0.7575
32.89%
0.1875
Schlusskurs vom Vortag:
$0.57
Offen:
$0.6521
24-Stunden-Volumen:
20,205
Relative Volume:
18.34
Marktkapitalisierung:
$N/A
Einnahmen:
$1.40M
Nettoeinkommen (Verlust:
$-1.78M
KGV:
-1.395
EPS:
-0.543
Netto-Cashflow:
$-1.09M
1W Leistung:
+32.89%
1M Leistung:
+110.42%
6M Leistung:
+3.06%
1J Leistung:
+3.06%
1-Tages-Spanne:
$0.6521
$0.7575
1-Wochen-Bereich:
$0.6521
$0.7575
52-Wochen-Spanne:
$0.31
$0.7575
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Firmenname
Avenue Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare ATXI vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.7575 | 0 | 1.40M | -1.78M | -1.09M | -0.543 |
VRTX
Vertex Pharmaceuticals Inc
|
517.00 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.33 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.44 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
134.73 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
204.08 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten
General Fusion Restates Q1, Cuts Net Loss by $411.3 Million - Minichart
Boston biotech Bicara signs sublease for Wayfair space - The Business Journals
Avenue Therapeutics Inc (OTC: ATXI) Share Price, ATXI Stock News, ATXI Share Price & Updates - kalkine.ca
Aptevo Therapeutics (APVO) quietly closes private funding round - Stock Titan
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates - The National Law Review
Postoperative Pain Management Clinical Trial Pipeline Accelerates as 45+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - Business Upturn
Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
State Street (NYSE: STT) discloses 5.5% beneficial stake in Lexeo Therapeutics (LXEO) - Stock Titan
Aprea Therapeutics, Inc. (APRE) stock price, news, quote and history - Yahoo Finance Singapore
State Street Corporation (ALLO) discloses 5.5% beneficial stake in Allogene - Stock Titan
Price to earnings forward of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView
Aldeyra Therapeutics (NASDAQ: ALDX) leases new Concord headquarters space - Stock Titan
Change Agents Corporation (CHGA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Avenue Therapeutics, Inc. Revenue Breakdown – OTC:ATXI - TradingView
Frontier tech research, news & data - MLQ.ai
Circio, Avenue Biosciences Partner on Gene Therapy Protein Expression - Contract Pharma
Cadrenal Therapeutics (CVKD) outlines $8.84M Rule 506(b) warrant financing - Stock Titan
Turn Therapeutics Inc.Common Stock (TTRX) Stock Price, News, Quote & History - FinancialContent
TG Therapeutics Initiates Phase 2 Trial of BRIUMVI in Treatment-Resistant Schizophrenia - Quiver Quantitative
Enterprise value to EBITDA forward of Avenue Therapeutics, Inc. – OTC:ATXI - TradingView
Price to sales forward of Avenue Therapeutics, Inc. – OTC:ATXI - TradingView
Price to book forward of Avenue Therapeutics, Inc. – OTC:ATXI - TradingView
Price to sales forward of Avenue Therapeutics, Inc. – LSX:A40BWJ - TradingView
Enterprise value to EBIT forward of Avenue Therapeutics, Inc. – OTC:ATXI - TradingView
Price to earnings forward of Avenue Therapeutics, Inc. – LSX:A40BWJ - TradingView
Avenue Therapeutics, Inc. Actuals & Estimates (OTC:ATXI) - TradingView
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares - Business Wire
Avenue Therapeutics (ATXI) Q1 2026 earnings summary - Quartr
Avenue Therapeutics (ATXI) Q3 2024 earnings summary - Quartr
Avenue Therapeutics (ATXI) AGM 2024 Summary - Quartr
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering - Business Wire
Definium Therapeutics, Inc. Announces Proposed Public Offering - BioSpace
Fortress Biotech StockSaturday deep dive on the business model - AD HOC NEWS
Madison Avenue Partners LP Reduces Stock Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - StreetInsider
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds - StreetInsider
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - StreetInsider
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - TradingView
Antibody may improve treatment response in lung cancer: Newsroom - UT Southwestern
Summit Therapeutics Announces Proposed Public Offering of Common Stock - FinancialContent
Tango Therapeutics Announces Proposed $500 Million Public Offering - The Manila Times
Neuro stocks outpace broader markets as psychedelics, Axsome shine - BioWorld News
Chiesi (KALV) offers $27.00/share; HSR, German and Italian clearances noted - Stock Titan
Relay Therapeutics Announces Proposed Public Offering of Common Stock - Investing News Network
Madison Avenue entities (INDV) disclose 4.32M-share, ~3.5% stake - Stock Titan
Priority review voucher sale drives Fortress Biotech (FBIO) Q1 2026 profit and cash surge - Stock Titan
Jeremy Levin reports 4.5% stake in Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
Click Therapeutics Positions Over-the-Counter Digital Therapeutics as New Growth Avenue - TipRanks
State Street (VNDA) discloses 3.02M shares, 5.1% ownership on 13G - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) Rating Increased to Hold at Wall Street Zen - MarketBeat
MSN Money - MSN
Finanzdaten der Avenue Therapeutics Inc-Aktie (ATXI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
Kapitalisierung:
|
Volumen (24h):